1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9436)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22058)
  2. Department of Medicine (22036)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5511)
  2. Elsevier Inc. (2650)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22058)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
    Meeting Abstract

    Conley, A. P.; Demetri, G. D.; Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Cassier, P.; Siena, S.; Ahn, M. J.; Buchschacher, G. L. Jr; Seto, T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy
    Meeting Abstract

    Liu, S. V.; De Braud, F.; Drilon, A.; Doebele, R. C.; Patel, M. R.; Cho, B. C.; Ahn, M. J.; Chiu, C. H.; Farago, A. F.; Goto, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
    Meeting Abstract

    Strickler, J.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F.; Hubbard, J.; Wu, C.; Stecher, M.; Walker, L. N.; Bekaii-Saab, T.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
    Meeting Abstract

    Ku, G.; Bendell, J. C.; Tolcher, A. W.; Hurvitz, S. A.; Krishnamurthy, A.; El-Khoueiry, A. B.; Patnaik, A.; Shroff, R. T.; Noonan, A.; Hahn, N. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
    Meeting Abstract

    Rugo, H. S.; Llombart Cussac, A.; André, F.; Robson, M.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Seok Ahn, J.; Nanda, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
    Meeting Abstract

    Kaufman, P. A.; Martin, M.; Mayer, I.; Vahdat, L. T.; Pernas Simon, S.; Schmid, P.; McArthur, H. L.; Dent, R.; Rugo, H. S.; Barrios, C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
    Meeting Abstract

    John, T.; Chiu, C. H.; Cho, B. C.; Fakih, M.; Farago, A. F.; Demetri, G. D.; Goto, K.; Doebele, R. C.; Siena, S.; Drilon, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
    Meeting Abstract

    André, T.; Amonkar, M.; Norquist, J.; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J.; Smith, D.; Garcia-Carbonero, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
    Meeting Abstract

    Hurvitz, S. A.; Chia, S. K. L.; Ciruelos, E. M.; Hu, X.; Im, S. A.; Janni, W.; Jerusalem, G.; Lacouture, M.; O'Regan, R.; Rugo, H. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Vahdat, L. T.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save